Lataa...
Targeting the ERK Signaling Pathway in Melanoma
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have opened a new era in the treatment of this tumor. Vemurafenib was the first specific kinase inhibitor approved for therapy of advanced melanomas harboring BRAF-activating mutations, followed by dabraf...
Tallennettuna:
| Julkaisussa: | Int J Mol Sci |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6472057/ https://ncbi.nlm.nih.gov/pubmed/30934534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20061483 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|